ClinicalTrials.gg
RecruitingNCT07935278INI TBIUpdated Nov 13, 2026

Repurposing Insulin With Intranasal Administration to Improve Function After Mild Traumatic Brain Injury

A Phase 2 interventional study of Insulin (Humulin) and Placebo in Concussion (Diagnosis) and Mild Traumatic Brain Injury, sponsored by HealthPartners Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by HealthPartners Institute · Phase 2, Interventional, and Treatment

Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 419 studies in Brain Concussion with a site in United States — 101 open to participants now, 122 under way, 5 of them phase 3. Brain Concussion · United States.

Planned enrollment
118th of 322
96 · median 60
Started
2026
with 23 others
Phase 2
24 of 419
9 open now
Primary completion
2027-11
later than 82 of 121 live
Registered
419th of 419
by date

Among the 419 studies in Brain Concussion with a site in United States, this one is the 118th largest by planned enrollment of the 322 interventional ones that give a count, is one of 24 that started in 2026, is one of 24 in phase 2, reaches primary completion later than 82 of the 121 other live ones, and was the 419th registered.

Brain Concussion

640 studies on the registry are indexed under Brain Concussion; 166 are open to participants now.

Browse Brain Concussion studies →

Open to participants now

101 of the 419 studies in Brain Concussion with a site in United States are open now. Recruiting first, the newest first:

95 more — sign in →

All 101 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 113 Brain Concussion studies recruiting now, 33 (29%) set no upper age limit and 73 (65%) stop at 75 or younger; 24 take children under 18; 38 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 419 studies in Brain Concussion with a site in United States, or all of them as a file.
02

Study summary

This Phase II clinical trial protocol will provide evidence as to whether IN insulin is efficacious in reducing symptoms in people seeking care for mild TBI (concussion).

03

Conditions studied

  • Concussion (Diagnosis)
  • Mild Traumatic Brain Injury

Keywords

  • intranasal
  • insulin
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has presented to a clinic/ER reporting an acute head injury (e.g., a closed head injury or blunt TBI) and presents with at least two symptoms of TBI, as defined by the listed symptoms on the Post-Concussion Symptom Scale (PCSS)
  • Subject is considered high risk for persistent post-concussion symptoms using the post-concussion symptom (PoCS) clinical decision rule
  • Subject is between ≥18 and ≤65 years of age
  • Treatment can be initiated within 5-14 days after injury, inclusive
  • Subject must be proficient in speaking English in order to comply with instructions and measures for the study
  • Subject must be able to consent
  • Female subjects of must have a negative pregnancy test at the baseline visit and be willing to use a medically acceptable method for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • Subject's concussion or TBI resulted in loss of consciousness of > 30 minutes
  • Subject has evidence of acute intracranial hemorrhage at screening
  • Subjects has received an intranasal vaccine within 2 weeks of the date of their baseline visit
  • Subject has medical history and/or clinically determined disorders: chronic sinusitis, previous nasal and/or oto-pharyngeal surgery, and severe deviated septum and/or other anomalies, including findings of an abnormal nasopharyngeal exam that could interfere with intranasal administration as judged by the PI, e.g., inflammation, erythema, bleeding, atrophy, septal perforation, mucosal erosion, localized infection or ulceration, polyposis.
  • Subject has history of any of the following: active and significant central nervous system, psychiatric illness, pulmonary, or cardiovascular disorders or any other abnormality that inclusion would pose a safety risk to the subject as determined by investigator
  • Subject has evidence of blast injury, electrocution injury, or significant multisystem trauma associated with the mTBI, including significant nasal trauma
  • Subject has participated in a clinical trial investigation (drug or device) within 3 months of this study.
  • Subject has an insulin allergy
  • Subject is taking insulin for Type I or Type II diabetes
  • Subject is pregnant or breast feeding
  • Subjects with nasal piercings or any physical finding in the nose that, in the opinion of the PI, would be likely to interfere with successful completion of dosing
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Dose 1 - 40 IU/IN (20 IU, twice daily x 21 days)

    Intranasal insulin, lower dose, 40 IU insulin, twice daily for 21 days

    Drug: Insulin (Humulin)

  • Experimental
    Dose 2 - 80 IU/IN (40 IU, twice daily x 21 days)

    Intranasal insulin, higher dose, 80 IU insulin, twice daily for 21 days

    Drug: Insulin (Humulin)

  • Placebo comparator
    Dose 3 - Placebo

    intranasal, twice daily for 21 days

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Post-Concussion Symptom Scale scores (PCSS) from baseline to 21 days

    The PCSS is a 22-item self-report inventory of concussion symptoms. Each symptom is rated for severity from 0 (none) to 6 (severe), giving a total score of 0 to 132; higher scores indicate greater symptom burden. Change is calculated as the Day 21 score minus the baseline score, so negative values indicate improvement. Each insulin arm (40 IU and 80 IU) is compared separately with saline, and results are reported as the difference in mean change (insulin minus saline) with a 97.5% confidence interval.

    Time frame: baseline and day 21 post-intervention

Secondary outcomes

  1. Differences in time to return to normal activities by day 21

    Number of days from intervention to participant-reported return to normal activities. Participants who have not reported a return to normal activities by Day 21 are censored at their last observation. Each insulin arm (40 IU and 80 IU) is compared separately with saline, and results are reported as a hazard ratio (insulin vs. saline) with a 95% confidence interval; a hazard ratio greater than 1 indicates faster return to normal activities with insulin.

    Time frame: baseline and day 21 post-intervention

  2. Change in Quality of Life after Brain Injury (QOLIBRI) scores from baseline to 21 days

    The QOLIBRI is a 37-item self-report measure of health-related quality of life after traumatic brain injury. The total score ranges from 0 to 100; higher scores indicate better quality of life. Change is calculated as the Day 21 score minus the baseline score, so positive values indicate improvement. Each insulin arm (40 IU and 80 IU) is compared separately with saline, and results are reported as the difference in mean change (insulin minus saline) with a 95% confidence interval.

    Time frame: baseline and day 21 post-intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 13, 2026
StartEst.
Nov 2026
Primary completionEst.
Nov 2027
CompletionEst.
Dec 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07935278
Responsible party
Sponsor
First posted
Nov 13, 2026
Start date
Nov 2026 (estimated)
Primary completion
Nov 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Clinical Research Coordinator
Contact
ClinicalTrials@HealthPartners.com
651-495-6363
Bhavani Kashyap, MBBS, PhD
principal investigator · HealthPartners Institute Neuroscience Research

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion